Recombinant EBV gp350/220 (Ectodomain)[His] (DAGA-3073)

EBV gp350/220 (Ectodomain)[His], Recombinant protein from 293 cell culture for WB, ELISA

Product Overview
C-terminal 6xHis tagged gp350/220 (RBD/(a.a.4-863))(EBV)(Genebank #: AHA36359).
Alternative Names
Epstein Barr Virus; EBV; Epstein–Barr virus; human herpesvirus 4; HHV-4; Human herpesvirus 4
Each vial contains 100 µg of purified protein (1 mg/ml) in PBS
Batch dependent - please inquire should you have specific requirements.
Keep it at 4 centigrade if used within a month. For long term storage, split it into small aliquots and keep at -80 centigrade. Avoid repeated freezing and thawing. The product will be expired one year after receiving if stored properly. Non-hazardous. No MSDS required.


Have you cited DAGA-3073 in a publication? Let us know and earn a reward for your research.

Related Products

EBV [His] (DAG1578)
EBV [GST] (DAG1580)
EBV [GST] (DAG1581)

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Gastric cancer: a comprehensive review of current and future treatment strategies


Authors: Sexton, Rachel E.; Al Hallak, Mohammed Najeeb; Diab, Maria; Azmi, Asfar S.

Gastric cancer remains a major unmet clinical problem with over 1 million new cases worldwide. It is the fourth most commonly occurring cancer in men and the seventh most commonly occurring cancer in women. A major fraction of gastric cancer has been linked to variety of pathogenic infections including but not limited to Helicobacter pylori (H. pylori) or Epstein Barr virus (EBV). Strategies are being pursued to prevent gastric cancer development such asH. pylorieradication, which has helped to prevent significant proportion of gastric cancer. Today, treatments have helped to manage this disease and the 5-year survival for stage IA and IB tumors treated with surgery are between 60 and 80%. However, patients with stage III tumors undergoing surgery have a dismal 5-year survival rate between 18 and 50% depending on the dataset. These figures indicate the need for more effective molecularly driven treatment strategies. This review discusses the molecular profile of gastric tumors, the success, and challenges with available therapeutic targets along with newer biomarkers and emerging targets.

Epstein-Barr virus infection and genome polymorphisms on gastric remnant carcinoma: a meta-analysis


Authors: Lu, Chao; Zhang, Hongtao; Zhou, Weihua; Wan, Xingyong; Li, Lan; Yu, Chaohui

BackgroundPrevious studies reported that Epstein-Barr virus (EBV) may play a causal role in the pathogenesis of gastric remnant carcinoma (GRC). However, there was still some controversy.MethodsArticles published until July 15, 2020, in PubMed, MEDLINE, Embase and CNKI databases were selected. According to the inclusion criteria, corresponding data of included articles were abstracted and used for statistical analysis.ResultsThirteen papers were finally enrolled, nine of which showed the result that the risk of EBV infection rate in the GRC was higher than conventional gastric carcinoma (OR=5.22, 95% CI 3.89-7.00). In addition, we found that EBV associated GRC (EBVaGRC) had higher rate of Billroth-II (OR=3.80, 95% CI 1.90-7.57), carcinoma in anastomotic site (OR=2.41, 95% CI 1.27-4.56) and diffuse type (Lauren classification) (OR=1.97, 95% CI 1.04-3.73),while sex, initial diagnosis and lymphocytic infiltration were calculated no statistical difference. By genetic polymorphism analysis, "V-val" subtype of EBNA1 (OR=21.84, 95% CI 11.92-31.76) and "C" subtype of BamHI-W1/I1 (OR=7.07, 95% CI 1.47-34.03) were observed to be highly expressed in EBVaGRC.ConclusionEBV infection rate in the GRC was higher. Further analysis showed that Billroth-II, carcinoma in anastomotic site and diffuse type (Lauren classification) were associated to EBVaGRC. Through analysis of EBV genome polymorphisms, we thought that "V-val" subtype of EBNA1 and "C" subtype of BamHI-W1/I1 may become predictor of EBVaGRC.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket